Literature DB >> 9359726

Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media?

R Dagan1, O Abramson, E Leibovitz, D Greenberg, R Lang, S Goshen, P Yagupsky, A Leiberman, D M Fliss.   

Abstract

Bacteriologic response to cefuroxime axetil and cefaclor administered for 10 days was evaluated in acute otitis media (AOM) in patients aged 6-36 months. Middle ear fluid culture was obtained by tympanocentesis before treatment, on day 4 or 5 after initiation of treatment, and if clinical relapse occurred before day 17. Bacteriologic failure was observed in 32% of patients receiving cefaclor versus 15% of patients receiving cefuroxime axetil (P = .009). Failure rates increased with increasing MIC: For Streptococcus pneumoniae, 0.5 microg/mL (established as cutoff value for cefuroxime by the National Committee for Clinical Laboratory Standards [NCCLS]) discriminated between success and failure. For Haemophilus influenzae, high failure rates were observed for cefaclor, even with low MICs (< or = 1.0 microg/mL), and with both drugs they tended to increase with increasing MIC, even for values below the cutoff suggested by the NCCLS (8.0 and 4.0 microg/mL for cefaclor and cefuroxime, respectively). Thus, for AOM caused by H. influenzae, lower susceptibility cutoff levels for MICs should be established.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359726     DOI: 10.1086/514120

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Assumed versus approved breakpoints.

Authors:  D A Preston; M R Turnak
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

4.  Can the choice of antibiotics for therapy of acute otitis media be logical?

Authors:  R Dagan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-01       Impact factor: 3.267

5.  Interleukin 8 in middle ear fluid during acute otitis media: correlation with aetiology and bacterial eradication.

Authors:  E Leibovitz; R Dagan; J H Laver; L Piglansky; S Raiz; M R Abboud; D M Fliss; A Leiberman; A Barzilai
Journal:  Arch Dis Child       Date:  2000-02       Impact factor: 3.791

Review 6.  Appropriate treatment of acute otitis media in the era of antibiotic resistance.

Authors:  Ron Dagan
Journal:  Paediatr Drugs       Date:  2010-06-29       Impact factor: 3.022

7.  Efficacy of linezolid in experimental otitis media.

Authors:  S I Pelton; M Figueira; R Albut; D Stalker
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 8.  Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Petros I Rafailidis; Anastasios Kapaskelis; Konstantinos Z Vardakas
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

9.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

10.  In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.